CL2016002735A1 - Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer - Google Patents

Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer

Info

Publication number
CL2016002735A1
CL2016002735A1 CL2016002735A CL2016002735A CL2016002735A1 CL 2016002735 A1 CL2016002735 A1 CL 2016002735A1 CL 2016002735 A CL2016002735 A CL 2016002735A CL 2016002735 A CL2016002735 A CL 2016002735A CL 2016002735 A1 CL2016002735 A1 CL 2016002735A1
Authority
CL
Chile
Prior art keywords
quinolin
imidazo
compounds
treat cancer
ona
Prior art date
Application number
CL2016002735A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Kurt Gordon Pike
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2016002735A1 publication Critical patent/CL2016002735A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>COMPUESTOS DERIVADOS DE IMIDAZO[4,5-C]QUINOLIN-2-ONA; COMPOSICIÓN FARMACÉUTICA Y SU USO PARA TRATAR EL CÁNCER.</p>
CL2016002735A 2014-05-08 2016-10-27 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer CL2016002735A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461990232P 2014-05-08 2014-05-08

Publications (1)

Publication Number Publication Date
CL2016002735A1 true CL2016002735A1 (es) 2017-02-10

Family

ID=53264681

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002735A CL2016002735A1 (es) 2014-05-08 2016-10-27 Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer

Country Status (38)

Country Link
US (4) US9428503B2 (es)
EP (1) EP3140303B1 (es)
JP (1) JP6505131B2 (es)
KR (1) KR102013021B1 (es)
CN (1) CN106255692B (es)
AP (1) AP2016009532A0 (es)
AR (1) AR100340A1 (es)
AU (1) AU2015257456B2 (es)
CA (1) CA2946459C (es)
CL (1) CL2016002735A1 (es)
CR (1) CR20160523A (es)
CY (1) CY1120248T1 (es)
DK (1) DK3140303T3 (es)
DO (1) DOP2016000281A (es)
EA (1) EA031674B1 (es)
ES (1) ES2670416T3 (es)
HR (1) HRP20180697T1 (es)
HU (1) HUE037558T2 (es)
IL (1) IL248397B (es)
LT (1) LT3140303T (es)
MA (1) MA39960A (es)
MX (1) MX2016014639A (es)
NI (1) NI201600166A (es)
NO (1) NO2714752T3 (es)
NZ (1) NZ726042A (es)
PE (1) PE20170403A1 (es)
PH (1) PH12016502168A1 (es)
PL (1) PL3140303T3 (es)
PT (1) PT3140303T (es)
RS (1) RS57223B1 (es)
SG (1) SG11201609164VA (es)
SI (1) SI3140303T1 (es)
SV (1) SV2016005312A (es)
TN (1) TN2016000458A1 (es)
TR (1) TR201807101T4 (es)
TW (1) TWI662034B (es)
UY (1) UY36112A (es)
WO (1) WO2015170081A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2880626T3 (es) * 2015-04-02 2021-11-25 Merck Patent Gmbh Imidazolonilquinolinas
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
MA43733A (fr) * 2016-03-21 2018-11-28 Astrazeneca Ab Composés cinnolin-4-amine et leur utilisation pour traiter le cancer
CA3015953A1 (en) 2016-04-07 2017-10-12 Astrazeneca Ab N,n-dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide as atm (ataxia telangiectasia mutated) kinase modulator for treating cancer
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
SI3558997T1 (sl) 2016-12-20 2021-07-30 Astrazeneca Ab Spojine amino-triazolopiridina in njihova uporaba v zdravljenju raka
EP3567041B1 (en) * 2017-01-09 2023-12-27 Impact Therapeutics (Shanghai), Inc Substituted fused heteroaryl compound serving as a kinase inhibitor, and applications thereof
CN106692147A (zh) * 2017-02-07 2017-05-24 李明英 一种治疗男性不育的药物组合物
CN106798741A (zh) * 2017-02-07 2017-06-06 宫英 一种治疗抑郁症的药物组合物
CN106822123A (zh) * 2017-02-09 2017-06-13 王艳苓 一种治疗心脑血管疾病的药物组合物
US11547703B2 (en) 2017-02-27 2023-01-10 Impact Therapeutics (Shanghai), Inc Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
WO2019057757A1 (en) 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2019201283A1 (en) * 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
US20220047595A1 (en) * 2018-09-14 2022-02-17 Suzhou Zanrong Pharma Limited 1-ISOPROPYL-3-METHYL-8-(PYRIDIN-3-YL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-c]CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF
CA3131156A1 (en) * 2019-03-05 2020-09-10 Astrazeneca Ab Fused tricyclic compounds useful as anticancer agents
TW202102497A (zh) * 2019-03-29 2021-01-16 瑞典商阿斯特捷利康公司 化合物及它們在治療癌症中之用途
CN111909147B (zh) * 2019-05-10 2021-07-20 山东轩竹医药科技有限公司 Dna-pk抑制剂
CN114026097B (zh) * 2019-07-10 2024-02-23 上海瑛派药业有限公司 取代的吡唑并喹唑啉酮化合物及其应用
KR20220062003A (ko) * 2019-09-12 2022-05-13 임팩트 테라퓨틱스 (상하이), 인코포레이티드 치환된 이미다조퀴녹살린 화합물 및 이의 용도
WO2021139814A1 (zh) * 2020-01-09 2021-07-15 南京明德新药研发有限公司 喹啉并咪唑类化合物及其应用
US20230087844A1 (en) * 2020-01-13 2023-03-23 Shanghai Huayu Biotechnology Co., Ltd. Use of n2-quincline or isoquinoline substituted purine derivatives in cancer treatment
EP4171651A1 (en) 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and atm inhibitor
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2022193166A1 (en) * 2021-03-17 2022-09-22 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
DE602004014969D1 (de) 2003-11-21 2008-08-21 Novartis Ag 1h-imidazochinolinderivate als proteinkinaseinhibitoren
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2010003025A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
EA020715B1 (ru) 2009-06-04 2015-01-30 Новартис Аг ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА
EP2438063A1 (en) * 2009-06-04 2012-04-11 Novartis AG 1h-imidazo[4,5-c]quinolinone compounds, useful for the treatment of proliferative diseases
BR112012006802A2 (pt) * 2009-09-28 2020-08-18 F.Hoffmann-La Roche Ag composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN102199152A (zh) 2010-03-25 2011-09-28 高大新 杂环咪唑类磷脂激酶抑制剂
CN102372711B (zh) 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
KR20130124168A (ko) 2010-08-26 2013-11-13 히다치 겡키 가부시키 가이샤 건설기계
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
CN102399218A (zh) * 2010-09-16 2012-04-04 和记黄埔医药（上海）有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
MX2013006284A (es) 2010-12-06 2013-10-28 Piramal Entpr Ltd Derivados sustituidos de imidazoquinolina.
US20140287931A1 (en) 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
JP6042060B2 (ja) * 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用

Also Published As

Publication number Publication date
US9822111B2 (en) 2017-11-21
DOP2016000281A (es) 2016-12-15
TW201625609A (zh) 2016-07-16
CR20160523A (es) 2017-04-27
CA2946459A1 (en) 2015-11-12
TN2016000458A1 (en) 2018-04-04
PE20170403A1 (es) 2017-05-07
SG11201609164VA (en) 2016-12-29
EP3140303B1 (en) 2018-03-28
CY1120248T1 (el) 2019-07-10
AR100340A1 (es) 2016-09-28
CN106255692B (zh) 2019-02-26
CN106255692A (zh) 2016-12-21
US20190185468A1 (en) 2019-06-20
AU2015257456B2 (en) 2018-02-15
BR112016025153A8 (pt) 2021-07-20
JP2017514877A (ja) 2017-06-08
LT3140303T (lt) 2018-05-25
KR102013021B1 (ko) 2019-08-21
HRP20180697T1 (hr) 2018-06-01
KR20160147054A (ko) 2016-12-21
EA201692095A1 (ru) 2017-08-31
AP2016009532A0 (en) 2016-11-30
CA2946459C (en) 2022-07-12
UY36112A (es) 2015-10-30
NO2714752T3 (es) 2018-04-21
PH12016502168B1 (en) 2016-12-19
WO2015170081A1 (en) 2015-11-12
HUE037558T2 (hu) 2018-09-28
ES2670416T3 (es) 2018-05-30
BR112016025153A2 (pt) 2017-08-15
US9428503B2 (en) 2016-08-30
DK3140303T3 (en) 2018-06-06
EP3140303A1 (en) 2017-03-15
MA39960A (fr) 2018-03-28
US20150336952A1 (en) 2015-11-26
MX2016014639A (es) 2017-03-06
JP6505131B2 (ja) 2019-04-24
SV2016005312A (es) 2017-03-16
RS57223B1 (sr) 2018-07-31
PH12016502168A1 (en) 2016-12-19
US10189834B2 (en) 2019-01-29
TR201807101T4 (tr) 2018-06-21
IL248397B (en) 2019-02-28
NI201600166A (es) 2017-03-13
US20180134699A1 (en) 2018-05-17
US20160368920A1 (en) 2016-12-22
PT3140303T (pt) 2018-05-25
TWI662034B (zh) 2019-06-11
EA031674B1 (ru) 2019-02-28
NZ726042A (en) 2018-08-31
PL3140303T3 (pl) 2018-08-31
SI3140303T1 (en) 2018-06-29
AU2015257456A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
DOP2017000176A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CL2016001895A1 (es) Compuestos
CL2016000922A1 (es) Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4
CL2016001737A1 (es) Derivados heterocíclicos bicíclicos como inhibidores de bromodominio
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2015002932A1 (es) Inhibidores de proteína quinasa
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2015002897A1 (es) Inhibidores de bace1
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico